FDA approval of Lag3 will change the oncology landscape. Short term spikes and fluctuations on news won't tell us anything. We will need to wait for the industry to adapt and digest the new landscape and then we will see how the cards fall.
Imo, Immutep is advanced enough with its history of results with Efti and with the upcoming results in NSCLC for industry experts to form a reasonable analysis of where Efti will end up at the end of the day. If they ain't buying it within 12-18 months then you could reasonably assume that other emerging therapies have passed us by. Such is life in biotech. Not long to wait now.
Ann: Immutep receives FDA feedback for Efti development in MBC, page-37
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |